Supplementary Table 1. Statin therapy is associated with epigenetic modifications in individuals with type 2 diabetes

ABSTRACT

Aim: Statins lower cholesterol and reduce the
risk of cardiovascular disease. However, the exact mechanisms of statins remain
unknown. We investigated whether statin therapy associate with epigenetics in
type 2 diabetes (T2D) patients. Material & Methods: DNA methylation was
analysed in blood from newly diagnosed T2D patients from ANDIS and in a
replication cohort (ANDiU). Results: 79 sites were differentially methylated
between cases on statins and controls (FDR<5%) in ANDIS. These include
previously statin-associated methylation sites annotated to DHCR24
(cg17901584), ABCG1 (cg27243685), and SC4MOL (cg05119988). Differential
methylation of two sites related to cholesterol biosynthesis and immune
response, cg17901584 (DHCR24) and cg23011663 (ARIH2), were replicated in ANDiU.
Conclusion: Statin therapy associates with epigenetic modifications in T2D
patients.

摘要

目的：他汀类药物可降低胆固醇水平并减少心血管疾病风险，但他汀类药物的具体作用机制仍不明确。本研究旨在探讨他汀类药物治疗是否与2型糖尿病（type 2 diabetes, T2D）患者的表观遗传学存在关联。
材料与方法：对来自ANDIS队列的新诊断T2D患者及复制队列（ANDiU）的血液样本进行DNA甲基化分析。
结果：在ANDIS队列中，他汀类药物用药组与对照组之间存在79个差异甲基化位点（错误发现率false discovery rate, FDR<5%），其中包括先前已报道的与他汀类药物相关的、注释到DHCR24（cg17901584）、ABCG1（cg27243685）及SC4MOL（cg05119988）的甲基化位点。与胆固醇生物合成和免疫应答相关的两个位点——cg17901584（DHCR24）和cg23011663（ARIH2）的差异甲基化在ANDiU队列中得到验证。
结论：他汀类药物治疗与T2D患者的表观遗传修饰存在关联。